A nitric oxide-like factor mediates nonadrenergic-noncholinergic neurogenic relaxation of penile corpus cavernosum smooth muscle

N Kim, K M Azadzoi, I Goldstein, I Saenz de Tejada, N Kim, K M Azadzoi, I Goldstein, I Saenz de Tejada

Abstract

This study was initiated to characterize nonadrenergic-noncholinergic (NANC) inhibitory neurotransmission in penile corpus cavernosum. Using organ baths, isometric tension measurements were made in strips of human and rabbit corpus cavernosum. In examining endothelium-mediated responses, cumulative additions of exogenous acetylcholine elicited dose-dependent relaxations which were significantly reduced or completely inhibited in tissues treated with NG-monomethyl L-arginine (L-NMMA; an inhibitor of nitric oxide synthesis), oxyhemoglobin (a nitric oxide scavenger), or methylene blue (a guanylate cyclase blocker). Tissues exposed to hypoxic conditions (PO2 = 5-10 mmHg) also did not respond to exogenous acetylcholine. Mechanical removal of the endothelium in human corporal strips or in situ treatment of rabbit corpora with detergent blocked the relaxation to acetylcholine. Transmural electrical stimulation of corporal tissue strips denuded of functional endothelium, in the presence of adrenergic blockade with bretylium and muscarinic receptor blockade with atropine, caused frequency-dependent relaxation. This neurogenic relaxation was reduced or prevented by L-NMMA, oxyhemoglobin, methylene blue, and hypoxia. The effects of L-NMMA were reversed by L-arginine and the effects of hypoxia were readily reversed by normoxic conditions. Authentic, exogenous nitric oxide relaxed corporal strips which were contracted with adrenergic agonists and this effect was significantly inhibited by oxyhemoglobin. It is concluded that (a) endothelium-mediated responses of corpus cavernosum smooth muscle are mediated by a diffusible nitric oxide-like substance; (b) NANC neurogenic inhibitory responses do not require functional endothelium, and (c) nitric oxide, or a closely related substance, may act as an inhibitory neurotransmitter in penile corpus cavernosum smooth muscle.

References

    1. N Engl J Med. 1990 Jul 5;323(1):27-36
    1. Biochemistry. 1976 Sep 7;15(18):4059-64
    1. Biochem Biophys Res Commun. 1990 Jul 31;170(2):843-50
    1. Circ Res. 1990 Jun;66(6):1561-75
    1. Can J Physiol Pharmacol. 1981 Feb;59(2):150-6
    1. Nature. 1990 Oct 25;347(6295):768-70
    1. Nature. 1988 Nov 24;336(6197):385-8
    1. J Exp Med. 1989 Mar 1;169(3):1011-20
    1. Circ Res. 1989 Dec;65(6):1508-15
    1. Nature. 1987 Jun 11-17;327(6122):524-6
    1. Br J Pharmacol. 1989 Dec;98(4):1080-2
    1. Br J Pharmacol. 1989 Feb;96(2):418-24
    1. Nature. 1988 Jun 16;333(6174):664-6
    1. Biochem Biophys Res Commun. 1989 Apr 28;160(2):813-9
    1. J Pharmacol Exp Ther. 1989 May;249(2):524-8
    1. J Urol. 1989 Oct;142(4):1117-21
    1. N Engl J Med. 1989 Apr 20;320(16):1025-30
    1. Am J Physiol. 1988 Mar;254(3 Pt 2):H459-67
    1. Blood Vessels. 1985;22(6):301-5
    1. Nature. 1990 May 24;345(6273):346-7
    1. FASEB J. 1990 Mar;4(5):1494-500
    1. J Pharmacol Exp Ther. 1981 Oct;219(1):181-6
    1. Nature. 1980 Nov 27;288(5789):373-6
    1. Am J Surg Pathol. 1980 Jun;4(3):273-6
    1. Prog Hematol. 1979;11:115-45
    1. Br J Pharmacol. 1990 Mar;99(3):602-6

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe